Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Pegylated Liposomal Doxorubicin

Pegylated Liposomal Doxorubicin

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Pegylated Liposomal Doxorubicin

61 trials tracked of Pegylated Liposomal Doxorubicin: 12 in phase 3 or 4 and 6 with published results. The most-cited published study has 392 citations.

61Trials tracked
12Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 11 Phase 2 46 Phase 1 1 Other / NA 2
  1. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression Completed · 392 cited
  2. Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Completed · 287 cited
  3. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 221 cited
  4. Phase 3 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed · 192 cited
  5. Phase 3 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Completed · 63 cited
  6. Phase 3 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed · 43 cited
Show 44 more trials
  1. Phase 4 A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED) Completed
  2. Phase 3 A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer Completed
  3. Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed
  4. Phase 3 The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) Completed
  5. Phase 3 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer Completed
  6. Phase 3 A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma Completed
  7. Phase 2 Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer Completed
  8. Phase 2 Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) Completed
  9. Phase 2 Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer Completed
  10. Phase 2 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative Completed
  11. Phase 2 Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer Completed
  12. Phase 2 A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life Completed
  13. Phase 2 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer Completed
  14. Phase 2 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma Completed
  15. Phase 2 Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer Completed
  16. Phase 2 Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Completed
  17. Phase 2 A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer Completed
  18. Phase 2 Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer Completed
  19. Phase 2 Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma Completed
  20. Phase 2 Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma Completed
  21. Phase 2 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Completed
  22. Phase 2 Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed
  23. Phase 2 Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer Completed
  24. Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma Completed
  25. Phase 2 Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer Completed
  26. Phase 2 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Completed
  27. Phase 2 Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) Completed
  28. Phase 2 Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer Completed
  29. Phase 2 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer Completed
  30. Phase 2 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer Completed
  31. Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma Completed
  32. Phase 2 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
  33. Phase 2 Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer Completed
  34. Phase 2 Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma Completed
  35. Phase 2 Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) Completed
  36. Phase 2 Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma Completed
  37. Phase 2 Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma Completed
  38. Phase 2 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Completed
  39. Phase 2 A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
  40. Phase 2 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed
  41. Phase 2 Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia Completed
  42. Phase 2 p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 Completed
  43. Phase 2 S9912 Combination Chemo in Stage III Ovarian Cancer, Completed
  44. Phase 2 Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.